COMPOSITION

Olright ™ 20

OlmesartanMedoxomil 20mg Tablet


Olright ™ 40

OlmesartanMedoxomil 40mg Tablet


SUMMARY

Olmesartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently.
 
Mechanism of action
Olmesartan is a prodrug that works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.
 
Absorption
Olmesartan is slowly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 6-12 hour following oral administration. Its estimated bioavailability is 64-90%. Absorption is not affected by food.
 
Metabolism
Metabolized extensively (90%) to inactive metabolites via the cytochrome P450 3A4 isozyme.
 
Route of elimination
Olmesartan is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.
 
Indications
It is used to treat high blood pressure (hypertension). Olmesartan lowers blood pressure by relaxing the blood vessels.
Benefits of being on this drug can include a reduction in blood pressure which is associated with a reduction in the risk of stroke, attack, heart or kidney failure.
 
Side Effect
Dizziness, Peripheral oedema, Cold or flu-like symptoms, Chest pain, rhinitis, pharyngitis, Bronchitis.
 
Contraindications
Contraindications for treatment with olmesartan include biliary obstruction (BNF). Another major contraindication is pregnancy; reports in the scientific literature reveal fetal malformations for pregnant women taking sartan-derived drugs.